Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Advanced Medical Solutions upbeat on first-half growth
(Sharecast News) - Advanced Medical Solutions updated the market on its trading in the six months ended 30 June on Monday, highlighting significant revenue growth and strong performance from its US LiquiBand product line. The AIM-traded firm said group revenue for the first half was projected to be around £68m, marking a 10% increase on a constant currency basis and an 8% rise at reported exchange rates, compared to £63.1m in the first six months of 2023.
That growth was primarily driven by the US market, where LiquiBand sales had surged following the implementation of a new marketing strategy in the third quarter of last year.
The board said the enhanced commitment from partners and the promotion of LiquiBand XL across all three hospital distribution channels had significantly contributed to the positive outcome.
Adjusted profit before tax for the period was anticipated to be between £14.4m and £14.8m, up from £13.8m in the same period last year.
Looking ahead, AMS said it was optimistic about its performance for the full 2024 financial year.
Despite ongoing challenges in the wound care sector, the group said it expected to achieve double-digit top-line growth, excluding contributions from the recently acquired Peters Surgical.
The company's consolidated revenues and adjusted profit before tax were set to align with management's projections.
AMS said the recent acquisition of Peters Surgical, completed on 1 July, was expected to bring substantial benefits to the firm, including cross-selling opportunities and operational synergies that would enhance the group's performance over the next three years.
"We are very pleased to be able to report such a strong H1 performance and to confirm that 2024 remains on track," said chief executive officer Chris Meredith.
"We look forward to building on this strong start to the year.
"As we consolidate Peters Surgical in the second half, this nearly doubles our surgical sales, significantly expands our distribution capabilities and establishes the group as a global powerhouse in tissue-healing, solidifying our strategy for significant and sustainable growth in the long-term."
AMS said it was scheduled to release its interim results in September.
At 1127 BST, shares in Advanced Medical Solutions Group were up 0.88% at 229p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.